Beam Therapeutics (BEAM) Net Margin (2019 - 2026)
Beam Therapeutics (BEAM) reported Net Margin of 297.18% for Q1 2026, up 115302.0% year-over-year from N/an in Q1 2025, and down 238.81% quarter-over-quarter from 214.09% in Q4 2025.
Beam Therapeutics (BEAM) Net Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Net Margin data on file, last reported at 297.18% in Q1 2026.
- Net Margin for Q1 2026 came in at 297.18%, up 115302.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 39.66% (up 56811.0% YoY), and the FY2025 annual result was 57.24%, up 53588.0% from the prior year.
- Net Margin fell to 297.18% in Q1 2026 per BEAM's latest filing, from 214.09% in the prior quarter.
- Over five years, Net Margin peaked at 214.09% in Q4 2025 and troughed at 1450.2% in Q1 2025.
- A 5-year average of 614.62% and a median of 558.88% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2024: Net Margin surged 335851248 bps in 2022, then plunged 93310 bps in 2024.
- A 5-year view of Net Margin shows it stood at 191.39% in 2022, then soared by 124 bps to 45.16% in 2023, then sank by 765 bps to 300.51% in 2024, then jumped by 171 bps to 214.09% in 2025, then tumbled by 239 bps to 297.18% in 2026.
- Business Quant data shows BEAM's Net Margin at 297.18% in Q1 2026, 214.09% in Q4 2025, and 1162.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -297.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -297.18% |
| Dec 31, 2025 | 214.09% |
| Sep 30, 2025 | -1,162.38% |
| Jun 30, 2025 | -1,208.26% |
| Mar 31, 2025 | -1,450.20% |
| Dec 31, 2024 | -300.51% |
| Sep 30, 2024 | -677.47% |
| Jun 30, 2024 | -773.45% |
| Mar 31, 2024 | -1,331.57% |
| Dec 31, 2023 | 45.16% |
| Sep 30, 2023 | -558.88% |
| Jun 30, 2023 | -411.49% |
| Mar 31, 2023 | -398.46% |
| Dec 31, 2022 | -191.39% |
| Sep 30, 2022 | -693.56% |
| Jun 30, 2022 | -432.08% |
| Mar 31, 2022 | -820.85% |
| Dec 31, 2021 | -126.71% |
| Sep 30, 2021 | -3,685.19% |
| Jun 30, 2021 | -1,270,883.33% |